Slide 1: Elekta Innovation and Growth
Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation
Slide 2: Innovation and Growth
• Introduction Tomas Puusepp 15.00 • Partner in cancer care President and CEO • Growth • Patient-focused development • Cancer care solutions Dee Mathieson 15.30 • Agility™ SVP, Elekta Oncology • Clarity® 16.00 Q&A ESTRO 2012 Innovation and Growth
Slide 3: Elekta – one of the fastest growing companies in radiation therapy
Elekta – one of the fastest growing companies in radiation therapy • Every year over 1,000,000 patients benefit from treatment with radiation therapy equipment from Elekta • One of the fastest growing companies in the radiation therapy field • More than 3,300 employees worldwide* • Net sales (rollin
Slide 4: Elekta is a leader and pioneer in modern cancer care
Elekta is a leader and pioneer in modern cancer care Elekta Elekta Neuroscience Oncology No. 1 No. 2 Elekta Elekta Brachytherapy Software Solutions No. 1 No. 1 (OIS)
Slide 5: High growth and improved margins
High growth and improved margins MSEK Net Sales MSEK Profitability
Slide 6: Leading product portfolio with an increasing share of recurrent revenues
Leading product portfolio with an increasing share of recurrent revenues Service Aftermarket and software Hardware Net sales last 12 Leksell Gamma Knife® Service and maintenance months: SEK 8.5 bn 43% 57% Linear accelerators (linacs) Software Brachytherapy
Slide 7: Cancer – a major disease
Cancer – a major disease Cause of death in USA 2010 Cardiovascular disease 24% Cancer 23% Chronic lung disease 6% Cerebrovascular disease 5% Accidents 5% Alzheimer 3% Diabetes mellitus 3% Nephritis, nephrotic syndrome 2% Source: Centers for Disease Control and Prevention, preliminary data from 2010.
Slide 8: Increasing population with cancer
Increasing population with cancer 1. Number of new cancer cases 2. Increasing population living Millions with cancer 25 • Improved treatments - cancer Total becomes more of a chronic 20 disease 15 Men • Re-treatments 10 Women 5 0 2010 2015E 2020E 2025E 2030E • World population growth to 2030: +20% •
Slide 9: Elekta has strengthened its position in global radiotherapy
Elekta has strengthened its position in global radiotherapy Trend Varian 45% Elekta 35% Accuray 9% Siemens 9% Others 2% Note: Order intake. Sources – company reports
Slide 10: Strategy going forward
Strategy going forward 2011 – Focus on delivering value with solutions - 2011 ”From machine 1st Priority to systems” Accelerate growth – from systems to solutions - 2005 ”Perfecting the 2nd Priority Grow the margin and establish machine” industry leading efficiency
Slide 11: Product development focused on benefits for the patient
Product development focused on benefits for the patient Information Treatment • Learn about cancer • Individualized • Description of radiation treatments modality • Combination of technologies Consultation Follow-up • Education about radiation therapy • Data management • Demonstrating • Informatics
Slide 12: Agility - the most advanced solution for precise beam shaping
Agility™* - the most advanced solution for precise beam shaping • Outstanding beam shaping • Minimize unwanted dose • Confidence to treat what is planned • Shorter treatment times *Not for sale or distribution in all markets depending on status of approval and clearances.
Slide 13: Agility - excellent commercial potential
Agility™* - excellent commercial potential • Leading system on the market – Outstanding benefits for the patients – Unmatched product specifications • Potential to upgrade existing installed base – ~40% of installed base could theoretically buy an upgrade – US filing for approval submitted • Very go
Slide 14: Elekta is growing in North America
Elekta is growing in North America • Order intake +14% (local currency) during first nine months – Focus on comprehensive solutions – Good development with larger accounts – ~85% of revenues from hospital segment • Mainly a replacement market – Replacement cycle driven by new technology, age of inst
Slide 15: Elekta is the market leader in Europe
Elekta is the market leader in Europe • Order intake +11% (local currency) during first nine months – Good development in Northern Europe and emerging markets – Strong interest for Agility™ – Weaker market in Southern Europe • Mainly a replacement market – Market driven by replacement of old technol
Slide 16: Potential to gain installed base market share
Potential to gain installed base market share • Aging installed base on mature markets • Competitor with approx. 2,000 installed linear accelerators is exiting the market • Elekta has strong connection with MOSAIQ® software • With Agility™, Elekta has the most comprehensive offering on the market El
Slide 17: Leadership and strong growth on emerging markets
Leadership and strong growth on emerging markets • Leading market positions • Focus on education and training • Product development also specialized for emerging markets 2015E 2010/11 2004/05 20% 30% 40% 60% 70% 80% Emerging markets Mature markets *Net sales, rounded figures
Slide 18: We are just at the beginning of the curve
We are just at the beginning of the curve Health care spend per capita and installed linacs per million inhabitants USD and units installed USA Linacs per million people Ireland Denmark Sweden1 Norway Japan Australia Switzerland Taiwan Germany Netherlands Belgium Austria UK France Italy Canada Spain
Slide 19: Acquisitions to support Elekta's growth
Acquisitions to support Elekta’s growth 1997 2003 • Philips Radiation • Neuromag Therapy Division 2006 • (80%) of Beijing 2008 2011 Medical Equipment • CMS • Nucletron Institute (BMEI) 1972 Elekta was founded 2005 2007 2010 • IMPAC Medical • 3D Line • Resonant Systems Medical • Medical Intelligence
Slide 20: Good demand expected to continue
Good demand expected to continue North and South America • Strong demand in North America • Good prospects for continued growth in Latin America Europe, Middle East and Africa • Stable growth in most established and emerging markets • Slower development in southern parts of Europe Asia Pacific • Str
Slide 21: Innovation and Growth
• Introduction Tomas Puusepp 15.00 • Partner in cancer care President and CEO • Growth • Patient-focused development • Cancer care solutions Dee Mathieson 15.30 SVP , Elekta • Agility™ Oncology • Clarity® 16.00 Q&A ESTRO 2012 Innovation and Growth
Slide 22: Elekta Innovation and Growth
Elekta Innovation and Growth Dee Mathieson SVP, Elekta Oncology
Slide 23: Our challenge
Our challenge █ Mortality █ Incidence Lung cancer Breast cancer Prostate cancer Global incidence, millions Global incidence, millions Global incidence, millions 2,2 1,7 2,9 1,4 1,7 0,9 1,5 0,5 0,3 2010 2030E 2010 2030E 2010 2030E • Constantly moving • Minimizing impact on • Motion management • Decre
Slide 24: Elekta research groups
Elekta research groups Helping to improve clinical outcomes • Delivers “evidence based medicine” • Managed and supported by MOSAIQ® • Incorporates continuous quality improvement and decision support Data feedback, outcomes reporting, quality assurance Screening & diagnostics Treatment planning Activ
Slide 25: Holistic approach to solution development
Holistic approach to solution development Software • Oncology information Hardware system (OIS) • Linear accelerators • Treatment planning • Brachytherapy • Neuroscience Education and training • Full offering within Enhancing technologies education/training • Image guidance • Sharing of best practic
Slide 26: Breast cancer
Breast cancer Integrated radiation technologies with closely-developed IT applications Practice management • Breast cancer pathway & guidelines • Patient selection support • Decision support system Technological Breast • IMRT / VMAT • Hypofractionation • Breast fixation • Lymph node • Soft tissue de
Slide 27: Demonstrated in the ESTRO exhibition
Demonstrated in the ESTRO exhibition
Slide 28: Comprehensive radiation therapy portfolio
Comprehensive radiation therapy portfolio Linac portfolio Brachytherapy Leksell Gamma Knife® Services TPS ® OIS Scheduling MOSAIQ Contouring Motion management
Slide 29: Confident patient set-up
Confident patient set-up . a Zz \ “) ELEKTA a
Slide 30: Integrated Imaging
Integrated Imaging XVI Intuity™ Clarity® MOSAIQ® iViewGTTM XVI Symmetry™
Slide 31: Intra fraction motion management
Intra fraction motion management 4D Imaging Symmetry™ Gating Response™ Intra fraction Image Guidance Clarity® Autoscan XVI 5.0 Response™ and XVI 5.0 are works in progress and not available for sale or distribution
Slide 32: Workflow efficiencies with Elekta
Workflow efficiencies with Elekta XVI MOSAIQ® VMAT Integrity™ Agility™ Simultaneous AFS Delivery time Further 30% 6.5 cm/sec image & CFS 70% reduction reduction Leaf speed reconstruction 2005 2008 2009 2010 2012 Treatment time
Slide 33: Agility - Intelligent beam shaping
Agility™ - Intelligent beam shaping High-resolution beam shaping • Truly multifunctional • Expand treatment capabilities Minimize unwanted dose • Exceptionally low transmission (0.5%) • Reduce the risk of inducing secondary tumours • Important for pediatrics Confidence to treat what is planned • 7th
Slide 34: Agility
Agility™ “ Agility enables a faster delivery of advanced radiotherapy treatments. Reduced treatment times will lead to a better experience for the patient and will improve access to the technology for the benefit of more of our patients.” Vivian Cosgrove, Ph.D., Head of Radiotherapy Physics, St. Jam
Slide 35: Human Care Makes the Future Possible
Human Care Makes = the Future Possible